Innovation Pharmaceuticals Inc (IPIX)

[warrenthomas4001]

Sitting in the ICU burn unit of Shands at University of Florida since 5/23/20, watching over a 17 year old member of our family with 40% third and fourth degree burns covering everything from head to waist has presented multiple moments that SCREAMED for Brilacidin. Burn victims experience a cytokine storm, primarily of iL1 and iL6. Cortisol and inflammation are off the charts. Kidneys shut down and/or become damaged. Then infection sets in. Opportunistic lung, blood, and then the mother of all infections: FUNGAL stemming from the fertile ground of necrotic tissue that can run as deep as bone. This boy is fighting skin and skin structure infection. He’s fighting self-destructive Inflammation. He’s fighting Fungal infection from Candida, Fusarium, Aspergillus, and Mucor and the current standard of treatment is Amphotericin-B, which is highly toxic to the kidneys, even as the kidneys are already failing under the burden of fluid loss and decreased cardiac efficiency. The patient is often on dialysis before Amphotericin-B is administered. Fungal infection by itself in the case of Mucor, imposes a 50-100% patient mortality. For older patients, it is a death sentence. Brilacidin’s MOA hits on every one of these battle fronts. Every single one, according to the data we have. A drug Specifically designed for Skin and Skin Structure Infections, Anti-inflammatory, Anti-Bacterial, Anti-Fungal, Anti-Viral, and surely more tolerable than the current standard of care for fungal infection. The moment this drug breaches the levy, wherever that breach occurs, I expect a cascade of demand for it in every field of medicine.